Armour submitted a product licence application for Heat Treated High Potency Factorate. Read more about Armour submitted a product licence application for Heat Treated High Potency Factorate.
Hoechst UK limited applied for a product licence for what would later be known as Haemate P. Read more about Hoechst UK limited applied for a product licence for what would later be known as Haemate P.
Travenol Laboratories Ltd submitted a product licence application for Hemofil-T. Read more about Travenol Laboratories Ltd submitted a product licence application for Hemofil-T.
Hyland Inter-Office memo attaching a booklet regarding AHF improvements. Read more about Hyland Inter-Office memo attaching a booklet regarding AHF improvements.
Hyland Inter-office memo regarding being aware of the fact that Behring were in the last stages of clinical trials of "hepatitis risk-free" AHF. Read more about Hyland Inter-office memo regarding being aware of the fact that Behring were in the last stages of clinical trials of "hepatitis risk-free" AHF.
Hyland/Travenol learned of Behringwerke's product which was treated to eliminate the risk of hepatitis. Read more about Hyland/Travenol learned of Behringwerke's product which was treated to eliminate the risk of hepatitis.
The Sub-Committee on Safety of Medicines (biological) recommended not licensing the Tisseel Kit, a blood product produced by Immuno. Read more about The Sub-Committee on Safety of Medicines (biological) recommended not licensing the Tisseel Kit, a blood product produced by Immuno.
Lord Glenarthur approved a letter which stated that "in the absence of any screening test for AIDS we must ensure that all donations are, as far as possible, free from the possibility of infection." Read more about Lord Glenarthur approved a letter which stated that "in the absence of any screening test for AIDS we must ensure that all donations are, as far as possible, free from the possibility of infection."
The DHSS contemplated accompanying a leaflet advising high risk groups against donation in the UK, with an explanation that the US FDA had introduced requirements for plasma collection which were designed to exclude donors from high-risk groups. Read more about The DHSS contemplated accompanying a leaflet advising high risk groups against donation in the UK, with an explanation that the US FDA had introduced requirements for plasma collection which were designed to exclude donors from high-risk groups.
MRC issued a brief on AIDS stating that, "over the last six months the possibility of transmission by blood transfusion has become increasingly apparent". Read more about MRC issued a brief on AIDS stating that, "over the last six months the possibility of transmission by blood transfusion has become increasingly apparent".